The biotech firm, which trades under the ticker GRAL, intends to provide insights into its current clinical initiatives and the application of its methylation-based platform. Investors and industry stakeholders can access a live broadcast of the session through the company’s investor relations portal. Following the event, the company plans to maintain an archived version of the webcast for a minimum of 30 days.

GRAIL currently focuses on utilizing next-generation sequencing and machine learning to identify multiple deadly cancer types before they reach advanced stages. Beyond initial screening, the company’s technology supports precision oncology efforts, including biomarker subtyping and the monitoring of treatment efficacy or recurrence. The firm maintains operations across Menlo Park, Washington, D.C., North Carolina, and the United Kingdom.